Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 …

ObjectivesInvestigate the efficacy and safety of nivolumab+ BV in patients with R/R PMBL from the phase 2 CheckMate 436 (NCT02581631).MethodsCheckMate 436 is an open-label, phase 1/2 study of nivolumab+ BV to treat CD30+ NHL. This expansion cohort enrolled patients with confirmed PMBL and R/R disease after either autologous hematopoietic cell transplantation (auto-HCT) or≥ 2 prior multi-agent chemotherapy regimens if auto-HCT ineligible. Patients received nivolumab (240 mg IV) and BV (1.8 mg/kg IV) every 3 weeks until disease progression or unacceptable toxicity. Primary endpoints: investigator-assessed ORR (per Lugano 2014) and safety.Results30 patients were treated with nivolumab+ BV. At baseline, median (range) age was 36 (19-83) years; patients received a median (range) of 2 (2-5) prior systemic therapies and 4 (13%) received prior auto-HCT. With a median follow-up of 11 months …